




COVID-19 Update

February 8, 2021 –slides include provisional data


★ National versus state trends in COVID-19 cases

UNITED STATES



	TOTAL REPORTED	ON FEB. 7	14-DAY CHANGE
Cases	27 million+	87,889	-31% ↘
Deaths	463,338	1,301	-8% ↘
Hospitalized		81,439	-26% ↘

ILLINOIS



	TOTAL REPORTED	ON FEB. 7	14-DAY CHANGE
Cases	1.1 million+	1,995	-38% ↘
Deaths	21,738	62	-21% ↘
Hospitalized		2,188	-27% ↘



Average daily COVID-19 cases per 100k population in the past week



Highest states
 SC (68/100K/day)
 AR
 OK
 TX
 KY

IL: 36th*
 (23/100K/day)

If Chicago were a state:
 45th* (17.1/100K/day)
 *includes Washington DC



Cook 80/102 counties

Average daily cases per 100,000 people in past week




Chicago: New COVID-19 cases continue to decline; rolling average now below 500 new cases per day. First target: <400 new




C

Confirmed daily COVID-19 Chicago resident cases and 7-day rolling average

● Total cases ● 7-day rolling average



Chicago: COVID test percent positivity continues to decline; rolling average now just below 5%, meeting target positivity.



Chicago: Hospital (non-ICU) bed occupancy from COVID-19 has been improving since 11/25. Hospital capacity is adequate.

Peak 7-day rolling average	1211 avg. occupied non-ICU beds 5/4/2020
Current Availability	22% 02/03/2021



COVID-19 acute/non-ICU beds occupied, daily counts and 7 day average, daily occupancy census (04/03/2020-02/03/2021)




Includes all Chicago hospitals. Hospitals report daily to CDPH via EMResource, beginning April 3 (acute non-ICU occupancy). Acute non-ICU bed counts include burn, emergency department, med/surg, other, pediatrics and psychiatry beds in Chicago hospitals. Includes Chicago and non-Chicago residents. Includes confirmed and suspected COVID-19 cases.

Chicago: ICU occupancy from COVID-19 has been improving since 12/15. ICU capacity is adequate.

Peak 7-day rolling average	501 avg. occupied ICU beds 4/30/2020
Current Availability	29% 02/03/2021



COVID-19 ICU beds occupied, daily counts and 7 day average, daily occupancy census (03/13/2020 - 02/03/2021)



Includes all Chicago hospitals. Hospitals report daily to CDPH via EMResource, beginning March 19. ICU bed count includes all adult and pediatric ICU beds in Chicago hospitals. Includes Chicago and non-Chicago residents. Includes confirmed and suspected COVID-19 cases. Beginning 4/24/2020, the definition of ICU status changed as requested by HHS.

Vaccine Administered


	Total Doses (1 st and 2 nd)
Administered at Chicago Sites (supplied by City of Chicago vaccine)	339,101 212,475 (63%) to Chicago residents 126,626 (37%) to non-Chicago residents*
Administered to Chicago Residents	270,824 212,475 (78%) at Chicago sites 58,349 (22%) at non-Chicago sites

1 in 13 Chicago residents has received a first dose of vaccine


1 in 12 Chicago residents **18+** has received a first dose of vaccine

1 in 6 Chicago residents **65+** has received a first dose of vaccine

1 in 13 Chicago residents has received at least a first dose of COVID vaccine




Putting that in perspective: More than 270,000 COVID-19 vaccine doses have gone to Chicago residents—which is already 30,000+ more than the total number of Chicago residents (238,360) ever diagnosed with COVID!






Chicago is receiving just 6,000 first doses of vaccine per day to stretch across the whole city. There are more than 700,000 Chicagoans eligible for vaccination in phase 1b, plus health care workers who remain eligible from 1a.

- Jan 17-23: 34,550 first doses
<5000 first doses/day
- Jan 24-30: 34,550 first doses
<5000 first doses/day
- Jan 31-Feb 6: 39,950 first doses
5700 first doses/day
- Feb 7-Feb 13: 42,050 first doses
6000 first doses/day
- Chicago residents eligible in Group 1b






99% of Chicago's allocated doses have been pushed out to providers. Meeting goal: 95%+





88% of Chicago's vaccine doses have been administered *and reported* 7 days after delivery (excluding doses held for and administered by the Long-term Care Facility program). **Met initial goal of 85%.**



U.S. Vaccine Development/Authorization Update



- **Pfizer/BioNTech** and **Moderna** have Emergency Use Authorization based on excellent safety and efficacy profiles and are in use as two-dose regimens in U.S.
- **Johnson&Johnson/Janssen--** has now submitted its trial data to FDA for review
 - FDA will hold advisory committee meeting to review data on **February 26**; if approved, **CDC's Advisory Committee on Immunization Practices (ACIP)** would meet shortly thereafter, *could* start shipping early **March**.
- **AstraZeneca/Oxford** is in use in UK, Europe, including some single-dose use, ongoing U.S. trials.
 - South Africa stopped using given decreased efficacy against variant.
 - Not yet submitted to FDA, would not expect possible approval until ?**April** at the earliest.
- **Novavax** had some initial delays in clinical trials and manufacturing issues
 - Recent British trial showed excellent safety and robust protection (though less in South Africa)
 - Recruiting for U.S./Mexico-based clinical trials has picked up (20K+ enrolled of 30K needed)
 - Could have clinical trial results later this spring, *if* successful, possibility of another vaccine by ? **May**
- **Sanofi/GSK**—trials underway, but company announced it would delay any possible release until late 2021 given “insufficient immune response in elderly”
- **Merck** terminated its two COVID vaccine clinical trials January 25--excellent safety but suboptimal efficacy, “focusing instead on therapeutics/treatment trials”